1-4 of 4
Qing Chang
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract P233: TAS0953/HM06 is effective in preclinical models of diverse tumor types driven by RET alterations

Igor Odintsov, Renate I. Kurth, Kota Ishizawa, Lukas Delasos, Allan J.W. Lui, Inna Khodos, Connor J. Hagen, Qing Chang, Marissa S. Mattar, Morana Vojnic, Siddharth Kunte, Annalisa Bonifacio, Claudio Giuliano, Elisa De Stanchina, Emily Cheng, Emanuela Lovati, Marc Ladanyi, Romel Somwar
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2021) 20 (12_Supplement): P233.
https://doi.org/10.1158/1535-7163.TARG-21-P233
Published: 01 December 2021
View article titled, Abstract P233: TAS0953/HM06 is effective in preclinical models of diverse tumor types driven by <em>RET</em> alterations
Journal Articles

Abstract C036: Discovery of IACS-13909, an allosteric SHP2 inhibitor that overcomes multiple mechanisms underlying osimertinib resistance

Yuting Sun, Brooke A Meyers, Sarah B Johnson, Angela L Harris, Barbara Czako, Jason B Cross, Paul G Leonard, Faika Mseeh, Maria E Di Francesco, Connor A Parker, Qi Wu, Christopher A Bristow, Jason P Burke, Caroline C Carrillo, Christopher L Carroll, Qing Chang, Ningping Feng, Sonal Gera, Gao Guang, Justin Kwang-Lay Huang, Yongying Jiang, Zhijun Kang, Jeffrey J Kovacs, Xiaoyan Ma, Pijus K Mandal, Timothy McAfoos, Robert A Mullinax, Michael D Peoples, Vandhana Ramamoorthy, Sahil Seth, Erika Suzuki, Christopher Conrad Williams, Simon S Yu, Andy M Zuniga, Giulio F Draetta, Joseph R Marszalek, Timothy P Heffernan, Nancy E Kohl, Philip Jones
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (12_Supplement): C036.
https://doi.org/10.1158/1535-7163.TARG-19-C036
Published: 01 December 2019
View article titled, Abstract C036: Discovery of IACS-13909, an allosteric SHP2 inhibitor that overcomes multiple mechanisms underlying osimertinib resistance
Journal Articles

A Human Monoclonal Antibody against Insulin-Like Growth Factor-II Blocks the Growth of Human Hepatocellular Carcinoma Cell Lines In vitro and In vivo

Daniel T. Dransfield, Edward H. Cohen, Qing Chang, Lindsay G. Sparrow, John D. Bentley, Olan Dolezal, Xiaowen Xiao, Thomas S. Peat, Janet Newman, Patricia A. Pilling, Tram Phan, Ilka Priebe, Gemma V. Brierley, Niksa Kastrapeli, Kris Kopacz, Diana Martik, Dina Wassaf, Douglas Rank, Greg Conley, Yan Huang, Timothy E. Adams, Leah Cosgrove
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2010) 9 (6): 1809–1819.
https://doi.org/10.1158/1535-7163.MCT-09-1134
Published: 09 June 2010
View article titled, A Human Monoclonal Antibody against Insulin-Like Growth Factor-II Blocks the Growth of Human Hepatocellular Carcinoma Cell Lines <em>In vitro</em> and <em>In vivo</em>
Open the PDF for A Human Monoclonal Antibody against Insulin-Like Growth Factor-II Blocks the Growth of Human Hepatocellular Carcinoma Cell Lines <em>In vitro</em> and <em>In vivo</em> in another window
Includes: Supplementary data
Journal Articles

Inhibition of EphA2 receptor tyrosine kinase activity by dasatinib in pancreatic cancer.

Qing Chang, Claus Jorgensen, Tony Pawson, David Hedley
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2007) 6 (11_Supplement): C174.
Published: 01 November 2007
View article titled, Inhibition of EphA2 receptor tyrosine kinase activity by dasatinib in pancreatic cancer.